MIT researchers identify enzymes driving lung cancer development

Researchers at the Massachusetts Institute of Technology (MIT) have identified specific enzymatic mechanisms that drive the early development of lung cancer, potentially opening doors for preventative therapies.

One study focused on the enzyme caspase-1. In laboratory experiments involving mice, researchers found that blocking this enzyme reduced the size and number of lung lesions. When the enzyme inhibitor was combined with an antibody against IL-1 beta, nearly 20 percent of the mice avoided tumor development entirely. This approach, known as ‘cancer interception,’ aims to stop the disease before it establishes itself in tissue.

Another aspect of the research, published in Nature Communications, identified the enzyme UCHL1 as a critical driver in lung adenocarcinoma. UCHL1 acts as a deubiquitinating enzyme that stabilizes proteins essential for cancer cell survival, allowing malignant cells to bypass natural cell death and maintain high metabolic rates even during nutrient deprivation.

These findings suggest that targeting specific metabolic and inflammatory pathways could provide new therapeutic targets to reduce tumor progression while minimizing impact on healthy tissue. The research was supported by the National Institutes of Health and the MIT Koch Institute for Integrative Cancer Research.